Structure Therapeutics

In honor of #InternationalWomensDay, our team in Shanghai welcomed a psychology expert to explore the importance of mindfulness, stress management, and self-care, followed by a meditation and yoga session. All team members were encouraged to participate in this wonderful opportunity for personal growth, relaxation, and empowerment. In addition, our team in South San Francisco participated in a series of webinars hosted by International Women's Day 2025, dedicated to this year’s #AccelerateAction theme. We are committed to fostering an inclusive workplace where women thrive and their voices are heard. #IWD2025

"We have to educate doctors and patients that there is no shame in having the disease, obesity." - Elizabeth Paul, Member of the Obesity Action Coalition Board During yesterday's #WorldObesityDay, we had the privilege of hosting Obesity Action Coalition (OAC) board member Elizabeth Paul at our office in South San Francisco. Liz advocates for body positivity, standing up against bias, and promoting care and respect from health professionals and more. Her personal journey is a powerful reminder of the need for innovative, accessible treatment options. Learn more about the Obesity Action Coalition and this week's #ObesityCareWeek here: https://lnkd.in/eyshuNVF

Today is #WorldObesityDay, a time to raise awareness and advocate for better care and solutions for those living with #obesity, which affects hundreds of millions worldwide.     At Structure, we're advancing oral #smallmolecule medicines designed to address obesity with a goal of providing more accessible and scalable treatment options for patients across the globe. Learn more about our development programs including an orally-available small molecule GLP-1, aleniglipron, and our #amylin-based molecule, ACCG-2671, here: https://lnkd.in/e3TJuMbH

Today, we reported financial results for the fourth quarter and full year ended December 31, 2024, and provided a business update. Read the top highlights below and view the full announcement here: https://lnkd.in/dZNZ8EQ3   ➡️ Aleniglipron (GSBR-1290) ACCESS and ACCESS II studies fully enrolled; data from both studies anticipated by year-end 2025 ➡️ Oral small molecule amylin receptor agonist (ACCG-2671) Phase 1 study initiation anticipated by year-end 2025

What better way to kick off the year than by bringing the full U.S. team together to celebrate our wins and set the stage for another year of growth. Congratulations to the recipients of our Foundation Awards. We believe strong foundations make bold visions possible. We recognized our U.S. teams for their dedication and contributions in helping to shape the future of Structure Therapeutics. We’re looking forward to more progress in 2025.

In honor of International Day of Women and Girls in Science, we are pleased to introduce our Women’s Leadership Network, Structure’s global internal organization dedicated to women’s empowerment, leadership and excellence. Hear from our founding members below on why we believe now is the perfect time to launch this initiative and our passion for uplifting the #WomenInScience at Structure and beyond. #WomenInSTEM #IDWGS

Last week, our team in Shanghai welcomed #LunarNewYear with a festive celebration including games, performers, traditional Chinese foods, good luck charms, and more. The Year of the Snake symbolizes deep thinking, intelligence, and a calm, strategic approach to challenges. These qualities inspire our work as we advance small molecule medicines for patients worldwide. Wishing our global team, partners, and community a year of success!

We have launched our new website! This transformation is more than a new look—it's a reaffirmation of our mission, our passion, and our relentless drive to make medicines more accessible to all. Patients are waiting for treatment options that are available, cost effective, and convenient. Explore our story and commitment to developing oral #smallmolecule therapeutics to treat #obesity and chronic diseases on our refreshed website here: https://structuretx.com/

What an exciting #JPM25! Our CEO Raymond Stevens shared our upcoming milestones and mission of greater accessibility for #obesity treatments with both CNBC's Angelica Peebles and Bloomberg's Katie Greifeld. #SmallMolecule approaches, like the ones we are taking here at Structure, hold promise for greater access to long-term treatment options for people living with #obesity, in both affordability and availability.   Learn more about our approach and our current Phase 2b clinical studies, ACCESS and ACCESS II for obesity in the clips below. ➡️ CNBC: https://lnkd.in/ePane2aV ➡️ Bloomberg: https://lnkd.in/eB-EAe4A

As we reflect on another remarkable year, we’re proud to celebrate the milestones that have shaped our journey at Structure. 2024 has been a testament to our team's dedication and our collective mission of advancing our clinical-stage pipeline in #obesity and in multiple disease areas including metabolic, cardiovascular, and others. With this momentum, we’re excited to move into 2025, to build on these achievements and continue making a meaningful impact. Thank you to everyone who has been along for our journey and helped us get to where we are today. From all of us at Structure, happy holidays, and we’ll see you in the new year!